A 35-year-old woman with acute leukemia undergoing chemotherapy develops persistent fever, cough, and nodular infiltrates on chest X-ray. Sputum culture and bronchoalveolar lavage show septate hyphae with acute-angle branching. What is the drug of choice for treatment?

Explanation

## Diagnosis: Invasive Aspergillosis **Key Point:** The clinical presentation of a neutropenic patient (acute leukemia on chemotherapy) with pulmonary nodules and septate hyphae with acute-angle (45°) branching is diagnostic of invasive aspergillosis, typically caused by *Aspergillus fumigatus*. **High-Yield:** Aspergillus species produce septate hyphae with characteristic acute-angle (45°) branching, distinguishing them from the non-septate, right-angle branching of Mucorales. ## Drug of Choice: Voriconazole **Clinical Pearl:** Voriconazole is the first-line and preferred agent for invasive aspergillosis because: - Superior CNS penetration compared to amphotericin B (important for CNS aspergillosis) - Excellent lung tissue penetration - Broad-spectrum activity against most Aspergillus species - Lower nephrotoxicity than conventional amphotericin B - Oral bioavailability allows transition from IV to PO **Mnemonic:** **VORI for Aspergillus** — VORIconazole is the drug of choice for invasive Aspergillosis. ## Aspergillus vs Mucormycosis Comparison | Feature | Aspergillus | Mucormycosis | | --- | --- | --- | | **Hyphae** | Septate | Non-septate | | **Branching angle** | Acute (45°) | Right angle (90°) | | **Risk factors** | Neutropenia, hematologic malignancy, transplant | Diabetes (especially DKA), hematologic malignancy, transplant | | **Common site** | Lungs, sinuses, CNS | Rhinocerebral, pulmonary, cutaneous | | **First-line drug** | Voriconazole | Liposomal amphotericin B | | **Azole resistance** | Susceptible | Intrinsically resistant | ## Treatment Algorithm for Invasive Aspergillosis ```mermaid flowchart TD A[Suspected Invasive Aspergillosis]:::outcome --> B[Confirm: Culture + Histology + Galactomannan antigen]:::action B --> C[Assess site: Pulmonary vs Sinuses vs CNS]:::decision C -->|Pulmonary| D[Voriconazole IV 6 mg/kg Q12H x 1 dose, then 4 mg/kg Q12H]:::action C -->|Sinuses/CNS| E[Voriconazole IV same dosing]:::action D --> F{Clinical improvement at 2 weeks?}:::decision E --> F F -->|Yes| G[Continue IV or switch to oral voriconazole]:::action F -->|No| H[Consider L-AmB or combination therapy]:::action G --> I[Total duration: 6-12 weeks minimum]:::action H --> I ``` **Warning:** Fluconazole and itraconazole have poor activity against *Aspergillus fumigatus* and are NOT suitable for invasive aspergillosis. Liposomal amphotericin B is reserved for voriconazole-intolerant patients or CNS disease with poor voriconazole penetration (though voriconazole is still preferred). ## Dosing & Monitoring - **Voriconazole:** IV 6 mg/kg Q12H for 1 dose, then 4 mg/kg Q12H; oral 200 mg Q12H - **Therapeutic drug monitoring:** Trough level 1–5.5 mg/L (higher for CNS disease) - **Duration:** Minimum 6–12 weeks depending on site and clinical response - **Immune reconstitution:** Critical in neutropenic patients; increase CD4 count (if HIV+) or neutrophil recovery [cite:Harrison 21e Ch 201]